

### Periprocedural Management (Warfarin)

Pt bleeding risk factors? <ul style="list-style-type: none"> <li>Mjr bleed or ICH &lt; 3 months ago</li> <li>Plt abnormality (including ASA use)</li> <li>High INR</li> <li>Prior bleed during prev. bridging or similar proc.</li> </ul>	Procedure Bleed Risk (see bottom for examples)	Low thrombo risk <b>AF:</b> CHA <sub>2</sub> DS <sub>2</sub> -VASc ≤4 and no prior stroke/TIA/SE <b>VTE:</b> VTE >12 mos and no other risk factors <b>MHV:</b> Bileaflet AV prosth. w/o AF and no other stroke RFs	Moderate thrombo risk <b>AF:</b> CHA <sub>2</sub> DS <sub>2</sub> -VASc 5-6 or stroke/SE ≥ 3 mos ago <b>VTE:</b> VTE past 3-12 mos, non-severe thrombophilia, recurrent VTE, active CA (within 6 mos) <b>MHV*:</b> Bileaflet AV prosth. and one or more stroke RFs	High thrombo risk <b>AF:</b> CHA <sub>2</sub> DS <sub>2</sub> -VASc ≥ 7 or stroke/SE < 3 mos ago <b>VTE:</b> VTE < 3 months, severe thrombophilia <b>MHV:</b> any MV prosthesis, caged-ball or tilting disc AV prosth, recent (within 6 mos) stroke or TIA
No	Minimal/Low			
	Inter./ high			
	Uncertain			
Yes	All bleed risk categories			
Do not interrupt.	Likely interrupt. Don't bridge.	Likely interrupt. Likely don't bridge. (unless recent stroke, TIA, or SE)	Likely interrupt. Likely bridge. (unless major bleed or ICH<3 months)	Interrupt and Bridge.

\*Bridging in moderate risk MHV may be considered on an individualized basis after weighing bleed risk with risk of thromboembolism.

AV=aortic valve; SE=systemic embolization; stroke RFs= AF, prior stroke/TIA, HTN, DM, CHF, age>75

Min./Low bleed risk		Interm./High bleed risk			Uncertain bleed risk	
<ul style="list-style-type: none"> <li>Minor dental</li> <li>Cataract/ glaucoma</li> <li>Superficial incisions/ excisions</li> </ul>	<ul style="list-style-type: none"> <li>Pacemaker/defib implantation</li> <li>AF ablation(trans v.)</li> <li>Cervical/Prostate bx</li> <li>Cath/PCI(transradial)</li> <li>Diag. GI endoscopy</li> </ul>	<ul style="list-style-type: none"> <li>Complex dental (eg, extract &gt; 3 teeth)</li> <li>Cath/PCI (transfemoral)</li> <li>Lung bx</li> </ul>	<ul style="list-style-type: none"> <li>Hysterectomy</li> <li>Arterial revascularization</li> <li>Left atrial appendage occlusion</li> </ul>	<ul style="list-style-type: none"> <li>Highly vascularized organs (kidney, liver spleen)</li> <li>Cardiac, intracranial, or spinal</li> </ul>	<ul style="list-style-type: none"> <li>Extensive tissue injury (CA surgery arthroplasty)</li> <li>Lumbar puncture</li> <li>Most major surgeries &gt;45 min.</li> </ul>	<ul style="list-style-type: none"> <li>Esophageal bx</li> <li>Pericardiocentesis</li> </ul>

For full list of procedures, see online appendix to the 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management

### Stopping warfarin

INR result (5-7 days before procedure)	Supratherapeutic	Therapeutic	Subtherapeutic
When to start holding warfarin	At least 5 days before	5 days before	3-4 days before

### Bridging

Patient/ procedure factors	Bridging agent	Before Procedure		After Procedures	
		Start bridging agent	Stop bridging agent	Restart anticoagulants	Stop bridging agent
CrCl $\geq$ 30	LMWH	Start when INR < target or after 2-3 missed doses	24 hrs before procedure	Warfarin: within 24 hrs LMWH/UFH: within 24 hrs after low risk procedure; after 48-72 hrs in high bleed risk procedure	When INR in range
	UFH		At least 4 hrs before procedure and if aPTT is normal		
CrCl <30	UFH				
Pt with TE risk AND high bleed risk procedure	Individualized strategies to reduce bleed risk				
Heparin allergy or recent HIT	Follow local protocol	Follow local protocol	Follow local protocol	Follow local protocol	Follow local protocol

Adapted from: Doherty et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. DOI: 10.1016/j.jacc.2016.11.024; Douketis et al. Perioperative Management of Antithrombotic Therapy. Chest. 2012;141(2\_suppl):e326S-e350S. doi:10.1378/chest.11-2298; and Nishimura, et al. 2017 AHA/ACC Focused Update on VHD. Circulation. 2017;000:e000-e000. DOI: 10.1161/CIR.0000000000000503.

**Disclaimer:** This document is for informational purposes only and does not, itself, constitute medical advice. This document is not a replacement for careful medical judgments by qualified medical personnel. There may be information in this document that does not apply to or may be inappropriate for the medical situation at hand.

Copyright 2018, MAQI<sup>2</sup>. For questions or permissions, please email [info@maq2.org](mailto:info@maq2.org). Version 1, 1/21/18